Abstract: The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Abstract: Suggested is an antimicrobial mixture comprising or consisting of (a) at least one monocyclic sesquiterpene alcohol, (b) at least one active selected from the group consisting of 4-hydroxyacetophenone, sorbitan caprylate, cocamidopropyl PG-dimonium chloride phosphate, tetrasodium glutamate diacetate, glyceryl caprylate and glyceryl caprate, and optionally (c) at least one additional antimicrobial agent different from components (a) and (b).

Abstract: The present application relates to magnesium biotinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable biotin to mammals and treating or preventing symptoms of biotin deficiency.

Abstract: A wearable article, a moisturizing composition and a method for preparing a wearable article have been disclosed. The wearable article includes at least a layer of a flexible material, wherein the flexible material is an elastomeric material and an inner surface of the layer of flexible material is a coated with a coating formulation comprising 1% to 7% by weight of a moisturizing composition and 93% to 99% by weight of solvent. The moisturizing composition includes 10 to 30% by weight of at least one humectant and 1.0 to 5.4% by weight of at least one antioxidant. Thereby, the present invention reduces transepidermal water loss (TEWL) and promotes skin barrier recovery.

Abstract: Disclosed is a mucoadhesive pharmaceutical composition comprising a poly-ionic complex of chitosan and a polyacrylic acid polymer. As an oral formulation, the composition has the extended retention time in the gastrointestinal tract by its mucoadhesive and swelling properties, which is useful as sustained release formulations, retentive formulations of active ingredients with limited absorption regions, and active ingredients with pH dependent solubility.

Abstract: In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises free asenapine, a maleic acid alkali salt, and a rubber-based adhesive agent.

Abstract: The present disclosure relates to an active substance carrier comprising a core-shell network structure formed using a biopolymer. In an aspect of the present disclosure, the core-shell network structure comprises a core-shell particle comprising: a core comprising prolamin; and a shell comprising pullulan and pectin, wherein the pullulan comprised in the shell surrounds the core and the pectin is located in the outermost layer of the shell, so that a network is formed between the core-shell particles. It can effectively facilitate the transdermal absorption of an active substance.

Abstract: The present invention provides a method for controlling weeds comprising a step of treating a cultivation area of crops with ethyl [3-[2-chloro-4-fluoro-5-(1-methyl-6-trifluoromethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-3-yl)phenoxy]-2-pyridyloxy]acetate or flumioxazin before, simultaneously with, and/or after sowing crop seeds, which has an excellent efficacy for controlling weeds in a cultivation area of crops. The present invention also provides the above-mentioned method wherein the crops are the transgenic plant body or seeds that are tolerant to the protoporphyrinogen oxidase (PPO) inhibitors; and further provides the above-mentioned method wherein the crops are the transgenic plant body or seeds having any one of a polypeptide sequence selected from the group consisting of SEQ ID Nos. 1-32 described in the Description or a polypeptide sequence having at least 85% sequence identity to any one of SEQ ID Nos. 1-32.

Abstract: The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to DHODH inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders. The invention also relates to the local administration of such ophthalmic compositions, and in particular to their intravitreal administration. The invention relates also to controlled release formulations of therapeutically active agents, in particular of DHODH inhibitor compounds administered intraocularly, in particular in the posterior segment of the eye.

Abstract: A fibrous structure with a plurality of fibrous elements and agglomerated particles. The agglomerated particles can be matrix particles containing perfume.

Abstract: To provide a dental composition wherein the acid buffering capacity can be attained and the acid resistance of the tooth substance can be improved while maintaining very high foul breath inhibition capacity. A dental composition including: ion sustained-release glass; and a carrier for supporting the ion sustained-release glass, wherein the ion sustained-release glass is fluoroaluminoborosilicate glass having a composition range of: 15% to 35% by mass SiO2; 15% to 30% by mass Al2O3; 5% to 20% by mass B2O3; 20% to 45% by mass SrO; 5% to 15% by mass F; and 0% to 10% by mass Na2O.

Abstract: Disclosed are high-porosity protein particles useful for carrying one or more agents of interest, methods for their manufacture and use, and products comprising them.

Abstract: To provide a dental composition wherein the acid buffering capacity can be attained and the acid resistance of the tooth substance can be improved while maintaining very high foul breath inhibition capacity. A dental composition including: ion sustained-release glass; and a carrier for supporting the ion sustained-release glass, wherein the ion sustained-release glass is fluoroaluminoborosilicate glass having a composition range of: 15% to 35% by mass SiO2; 15% to 30% by mass Al2O3; 5% to 20% by mass B2O3; 20% to 45% by mass SrO; 5% to 15% by mass F; and 0% to 10% by mass Na2O.

Abstract: This invention is a novel method of manufacture for hand-sanitizing lotions that retains the added benefits of prolonged effectiveness while avoiding demulsification as well as the resulting product. The invention presents a novel, more simplified process comprising a lower cooking temperature and an optimized ingredient addition protocol, designed for product stability and ingredient integrity.

Abstract: A method to facilitate the growth of desired bacteria in a human's mouth by using a bioadhesive strip that has an encapsulated feature containing at least one bacteria that has one of a pathogenic or toxic element excised using a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system, and in particular, using oral strips that adhere to surfaces in the oral cavity and that include at least one of xylitol, Lachnospira, Veillonella, Faecalibacterium and/or Rothia bacteria.

Abstract: a film composite for manufacturing a package for planar carriers of pharmaceutical active substances, for example transdermal patches, encompassing, in a direction from the outer side of the film composite toward its inner side: a metal layer; an acrylic-acid-containing joining layer; a polyethylene layer; and a COC layer made of cycloolefin copolymer, a side of the COC layer which faces away from the metal layer being an exposed surface of the film composite, wherein provision is made that the polyethylene layer encompasses metallocene polyethylene.

Abstract: The inventive subject is directed towards ready-to-use topical cosmetic formulations that include at least one defensin present in sub-antimicrobially effective concentrations. Surprisingly, even at such low concentrations, defensins recruit LGR6+ stem cells from hair follicles to the interfollicular space. Including defensins in the inventive topical cosmetic formulations may reduce one or more of wrinkle depth, wrinkle length, wrinkle width, pore size, irregularity in texture of a skin surface, oiliness, brown spots, and red spots in non-injured skin, thus reducing apparent age.

Abstract: The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

Abstract: Cosmetic compositions are widely used to obtain certain benefits like e.g. anti-aging, skin lightening and moisturizing effect. These benefits are delivered by benefit agents (actives) like e.g. anti-oxidants, hyaluronic acid and resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol. However, these actives have a certain shelf life beyond which they tend to degrade in terms of chemical activity and/or their color stability. The present invention discloses a novel process to prepare cosmetic compositions that improved color stability of resorcinol, pheynylethyl resorcinol and 4-alkyl substituted resorcinol and compositions comprising such actives when prepared as per said process.

Abstract: The present invention provides thin-film forming compositions comprising an antiseptic (e.g., povidone iodine, chlorhexidine, or octenidine), a non-aqueous solvent, and a film-forming material dissolved in the non-aqueous solvent, wherein the composition yields a continuous and flexible protective film upon substantial removal of the solvent. The compositions are useful for the treatment and prevention of infections in wounds, ulcers (e.g., decubitus ulcers and stasis ulcers), cuts, or burns, or against infections from bacterial, mycobacterial, viral, fungal, or amoeba causes, as well as for prevention of such infections in appropriate clinical settings (e.g., as liquid bandages or dressings). Additionally, the compositions of this invention are also useful for the treatment of infections and as a disinfectant skin preparation for pre- and/or post-surgical operations.